Background

Bryan Johnson is an American technology entrepreneur whose career bridges payments technology, neurotechnology, and longevity protocols. He founded the online payment processor Braintree in 2007 and grew it to acquire Venmo before selling the combined entity to PayPal for $800 million in 2013. After the Braintree-PayPal sale, Johnson founded OS Fund in 2014 to invest in companies focused on rewriting the operating systems of life, and then founded Kernel in 2016.

Kernel

Kernel is a Los Angeles-based neurotechnology company developing non-invasive systems for measuring human brain activity at high resolution. The company’s Flow 2 helmet uses time-domain functional near-infrared spectroscopy (TD-fNIRS) to measure brain blood flow with sufficient temporal and spatial resolution to support research and potential clinical applications. Under Ryan Field’s CEO leadership, Kernel has shifted its commercial positioning toward providing high-quality brain-data collection-at-scale infrastructure to other companies developing models on neural data.

Blueprint

Johnson is also the architect of Blueprint, a longevity and anti-aging protocol that he has documented publicly through his own body, with the goal of reversing biological ageing through a regimented combination of diet, sleep, exercise, and supplementation tracked through extensive biomarker measurement. Blueprint has become a culturally visible reference point in the broader longevity-tech conversation and is widely referenced in coverage of the intersection of biohacking, neurotechnology, and human enhancement.

Strategic position

Johnson is one of the most public-facing figures at the intersection of consumer neurotechnology, biohacking, and human enhancement. He has been quoted in major mainstream press coverage of the BCI category (including Politico’s May 2026 feature on Silicon Valley brain-chip ambitions) as a representative voice of the transhumanist framing that the BCI industry has sometimes been associated with, even as most clinical-stage BCI companies are pursuing therapeutic applications rather than enhancement.